OakChart

Scholar Rock Holding Corp

SRRKHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

46.60-1.40 (-2.92%)
2026-11-12 04:06 CET
Market cap
5,675.18 USD m
Revenue, TTM
0.57 USD m
Net income, TTM
-413.61 USD m
Free cash flow, TTM
-309.91 USD m
EPS diluted, TTM
-3.36
P/E
-
Compare

Price

SRRK against its 20, 50 and 200-day averages
2050200beatearnings
40.0050.0060.003.8M7.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SRRKclose 46.6020-day 43.7850-day 46.64200-day 48.2546.6052w high

24.5% under the 52-week high of 61.76 on 26 Aug 2026. 52-week low 28.97 on 11 Nov 2025. Last 15 sessions, 28.2% high to low

Volume 0.86× normal · the line is the 50-bar volume average

Profile

SRRK
52-week range, 54% of the way up
28.9761.76

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

IndexRUT
Employees289
IPOMay 24, 2018
Beta0.78
ATR, 14d2.44
Rel volume0.86
Short float23.30%
Insider own17.26%
Inst own101.80%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.68B
Enterprise Value5.46B
Income-413.61M
Sales0.57M
Book/sh1.38
Cash/sh3.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees289
IPOMay 24, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S9956.47
P/B33.69
P/C13.64
P/FCF-
EV/EBITDA-
EV/Sales9582.76
Quick Ratio5.40
Current Ratio5.41
Debt/Eq1.20
LT Debt/Eq1.17
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.36
EPS next Y-2.60
EPS next Q-0.56
EPS this Y5.11%
EPS next Y16.68%
EPS next 5Y27.81%
EPS past 3/5Y-13.45% -3.21%
Sales past 3/5Y- -
EPS Y/Y TTM-3.43%
Sales Y/Y TTM-
EPS Q/Q9.87%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.4.39% 111.29%

Ownership

Insider Own17.26%
Insider Trans1.31%
Inst Own101.80%
Inst Trans4.52%
ROA-96.45%
ROE-199.97%
ROIC-113.06%
Gross Margin-132.11%
Oper. Margin-71732.28%
Profit Margin-72563.16%
SMA206.43%
SMA50-0.09%
SMA200-3.41%
Trades-

Technical

Shs Outstand121.93M
Shs Float100.76M
Short Float23.30%
Short Ratio13.54
Short Interest23.48M
52W High61.76 -24.55%
52W Low28.97 60.86%
Volatility7.51% 5.05%
ATR (14)2.44
RSI (14)53.64
Beta0.78
Rel Volume0.86
Avg Volume1.73M
Volume1,490,060

Performance

Perf Week1.11%
Perf Month15.00%
Perf Quarter-12.17%
Perf Half Y-7.12%
Perf YTD5.79%
Perf Year51.35%
Perf 3Y363.91%
Perf 5Y34.76%
Perf 10Y-
Recom1.11
Target Price69.12
Prev Close48.00
Price46.60
Change %-2.92%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 15, 2026DowngradeBBarclaysOverweight → Equal Weight$58+24.5%
Apr 21, 2026InitiatedCCanaccord GenuityBuy$62+33.0%
Jan 09, 2026InitiatedCCitigroupBuy$55+18.0%
Nov 18, 2025InitiatedWWolfe ResearchOutperform$42-9.9%
Oct 09, 2025InitiatedBBofA SecuritiesBuy$53+13.7%
Sep 17, 2025InitiatedBBarclaysOverweight$45-3.4%
Sep 15, 2025InitiatedLLeerink PartnersOutperform$51+9.4%
Aug 21, 2025ResumedJJefferiesBuy$50+7.3%
Jul 30, 2025ResumedRRaymond JamesStrong Buy$53+13.7%
Jul 17, 2025InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
BHVNBiohaven Ltd2.29B
PTCTPTC Therapeutics Inc5.42B
DYNDyne Therapeutics Inc3.37B
BIIBBiogen Inc37.46B
SRPTSarepta Therapeutics Inc1.79B
EWTXEdgewise Therapeutics Inc5.21B
REGNRegeneron Pharmaceuticals Inc99.23B
CYTKCytokinetics Inc8.15B
NVSNovartis AG ADR293.47B
KROSKeros Therapeutics Inc187.22M

Insider trading

latest 14 of 43
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
AKKARAJU SRINIVASDirectorOct 26 '26Buy41.59146,9706,112,4826,380,517Oct 27 07:47 PM
AKKARAJU SRINIVASDirectorOct 23 '26Buy41.32142,5005,887,4406,331,529Oct 27 07:47 PM
Katie PengDirectorOct 01 '26Proposed Sale48.321,00648,610Oct 01 04:19 PM
FLIER JEFFREY S.DirectorJul 01 '26Sale53.883,053164,49027,856Jul 06 04:30 PM
Gilman MichaelDirectorJul 01 '26Sale53.872,544137,05859,511Jul 06 04:30 PM
Burow KristinaDirectorJul 01 '26Sale53.743,053164,064114,657Jul 06 04:30 PM
Reed JoshuaDirectorJul 01 '26Sale53.743,053164,06719,518Jul 06 04:30 PM
Peng KatieDirectorJul 01 '26Sale53.885,446293,40534,301Jul 06 04:30 PM
Mohammed QatananiOfficerJul 06 '26Proposed Sale54.6811,704639,975Jul 06 04:22 PM
Joshua ReedDirectorJul 01 '26Proposed Sale54.793,053167,274Jul 01 04:58 PM
Jeffrey S. FlierDirectorJul 01 '26Proposed Sale54.793,053167,274Jul 01 04:55 PM
Kristina BurowDirectorJul 01 '26Proposed Sale54.793,053167,274Jul 01 04:52 PM
Michael GilmanDirectorJul 01 '26Proposed Sale54.792,544139,385Jul 01 04:46 PM
Katie PengDirectorJul 01 '26Proposed Sale54.795,446298,386Jul 01 04:44 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.810-0.847-0.8100.640.3018
2026Q22026-08-06-0.840-0.841-0.8410.000.0017
2026Q12026-05-07-0.830-0.800-0.8290.000.0017
2025Q42026-03-03-0.880-0.890-0.8820.000.0016
2025Q32025-11-14-0.900-0.842-0.8990.000.0613
2025Q22025-08-06-0.980-0.665-0.9760.000.0010
2025Q12025-05-14-0.670-0.681-0.6680.000.0010
2024Q42025-02-27-0.620-0.601-0.7080.000.009
2024Q32024-11-12-0.660-0.580-0.6640.000.009
2024Q22024-08-08-0.600-0.590-0.6040.000.009
2024Q12024-05-07-0.590-0.483-0.5930.000.009
2023Q42024-03-19-0.473-0.466-0.6070.000.008
2023Q32023-11-07-0.530-0.496-0.5260.000.008
2023Q22023-08-09-0.470-0.533-0.4730.000.008
2023Q12023-05-09-0.490-0.523-0.4950.000.008
2022Q42023-03-07-0.440-0.529-0.7600.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.850-1.886-1.85220.4918.08
2020FY-2.810-2.572-2.81415.4018.50
2021FY-3.590-3.449-3.59018.8219.17
2022FY-2.260-2.165-2.25633.1933.15
2023FY-1.990-1.899-1.9890.000.00
2024FY-2.470-2.429-2.4670.000.00
2025FY-3.290-3.437-3.2900.000.00
2026FY--3.122--16.47
2027FY--2.601--135.54
2028FY--1.238--379.15
2029FY-0.200--666.92
2030FY-2.080--1,015

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-101741116.271.12207.32
2026Q4S2026-10-20173105.321.609.80
2026Q4S2026-10-19173115.352.009.80
2026Q4S2026-10-09174105.352.009.80
2026Q4S2026-10-0717596.062.0020.00
2026Q4S2026-09-2417596.052.0020.00
2026Q4S2026-09-2117596.052.0020.00
2026Q4S2026-09-1817495.822.0020.00
2026Q4S2026-09-1417495.942.0220.00
2026Q4S2026-09-1316476.032.0220.00
2026Q4S2026-09-1116476.122.0220.00
2026Q4S2026-08-2016455.671.9610.50
2026Q4S2026-08-1216445.741.9610.50
2026Q4S2026-08-0716435.931.9610.50

Estimate history

EPS, annual-0.99-3.151-1.852-2.814-3.59-2.256-1.989-2.467-3.295-3.3629
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.664-0.708-0.668-0.976-0.899-0.882-0.829-0.841-0.81
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0020.49215.40318.81633.1930000.57
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000.57
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual25.24526.21829.79334.15235.20951.67375.97993.824108.461121.935
Period201720182019202020212022202320242025MRQ
Shares, quarterly80.08293.82494.8739699.171108.461119.104121.6121.935
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.570.000.000.0033.1918.8215.4020.490.00
Cost of Goods Sold Incl. D&A1.321.661.942.849.889.02--0.81
Gross Profit-0.75-1.66-1.94-2.8423.319.79---0.81
Selling, General and Administrative Excl. Other408.12382.99250.12168.45157.68139.7198.4172.7349.88
Research and Development209.74206.78182.61119.06114.5699.4470.1954.2236.31
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-408.87-384.64-252.05-171.29-134.37-129.92-86.88-54.54-50.69
Interest Expense13.996.896.84------
Unusual Expense3.340.000.000.000.000.000.00-0.06
Net Income Before Taxes-413.61-377.94-246.29-165.79-134.50-131.80-86.48-51.00-49.33
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-413.61-377.94-246.29-165.79-134.50-131.80-86.48-51.00-49.33
Net Income From Continuing Operations-413.61-377.94-246.29-165.79-134.50-131.80-86.48-51.00-49.33
Net Income-413.61-377.94-246.29-165.79-134.50-131.80-86.48-51.00-49.33
EPS (Recurring)-3.11-3.29-2.47-1.99-2.26-3.59-2.81-1.85-3.15
EPS (Basic, Before Extraordinaries)-3.36-3.29-2.47-1.99-2.26-3.59-2.81-1.85-3.15
EPS (Diluted)-3.36-3.29-2.47-1.99-2.26-3.59-2.81-1.85-3.15
EBITDA-407.56-382.99-250.12-168.45-124.48-120.90-83.01-52.24-49.88
Non-Operating Income (Expense)12.5913.6012.605.51-0.13-1.880.403.541.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense75.2475.6036.6327.1425.7023.1511.187.975.21
Price To Sales Ratio11,221.45---16.2548.4796.8317.71-
Gross Margin-132.11---70.2252.04---
Operating Margin-71,732.28----404.81-690.48-564.03-266.16-
Net Margin-72,563.16----405.21-700.46-561.47-248.88-
Shares Outstanding121.93108.4693.8275.9851.6735.2134.1529.7926.22
Market Capitalization5,675.185,675.184,046.041,356.29467.55872.091,632.49391.16579.69

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.570.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.270.300.340.420.420.420.390.40
Gross Profit0.30-0.30-0.34-0.42-0.42-0.42-0.39-0.40
Selling, General and Administrative Excl. Other106.36108.60101.6891.47103.13111.6976.7068.96
Research and Development53.8757.9451.4846.4550.0661.9848.2849.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-106.06-108.90-102.02-91.90-103.55-112.11-77.09-69.36
Interest Expense4.634.522.302.531.331.211.82-
Unusual Expense0.000.003.340.000.000.000.000.00
Net Income Before Taxes-107.24-109.90-105.51-90.97-102.22-110.03-74.72-66.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-107.24-109.90-105.51-90.97-102.22-110.03-74.72-66.45
Net Income From Continuing Operations-107.24-109.90-105.51-90.97-102.22-110.03-74.72-66.45
Net Income-107.24-109.90-105.51-90.97-102.22-110.03-74.72-66.45
EPS (Recurring)-0.81-0.84-0.81-0.88-0.90-0.98-0.67-0.71
EPS (Basic, Before Extraordinaries)-0.81-0.84-0.83-0.88-0.90-0.98-0.67-0.71
EPS (Diluted)-0.81-0.84-0.83-0.88-0.90-0.98-0.67-0.71
EBITDA-105.80-108.60-101.68-91.47-103.13-111.69-76.70-68.96
Non-Operating Income (Expense)3.463.522.153.462.663.284.182.90
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.9119.6618.2519.4218.3324.4313.419.50
Price To Sales Ratio11,221.45-------
Gross Margin53.33-------
Operating Margin-18,607.19-------
Net Margin-18,813.86-------
Shares Outstanding121.93121.60119.10108.4699.1796.0094.8793.82
Market Capitalization5,675.186,590.545,647.654,493.413,579.783,362.973,043.864,046.04

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments367.56437.28279.94315.36252.99341.03157.45175.6557.96
Short Term Receivables2.802.151.080.000.000.0025.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets14.7911.747.1812.6612.323.372.722.301.24
Total Current Assets385.15451.17288.19328.02265.32344.40185.17177.9459.20
Net Property, Plant & Equipment12.0918.4116.0225.9335.0140.388.623.192.18
Total Investments and Advances3.812.412.412.502.502.502.500.200.20
Intangible Assets0.000.000.00----0.00-
Other Assets3.232.944.421.721.621.020.100.000.05
Total Assets404.27474.92311.04358.17304.44388.31196.38181.3461.64
Short Term Debt Incl. Current Port. of LT Debt5.555.778.747.858.985.371.140.440.64
Accounts Payable10.3010.103.463.994.433.411.133.301.36
Other Current Liabilities39.5731.0720.5324.5450.8833.7930.5527.383.02
Total Current Liabilities55.4246.9432.7436.3964.3042.5632.8131.125.02
Long Term Debt103.3659.3553.0861.5468.0751.774.170.020.40
Provision for Risks Charges0.000.000.000.000.000.000.000.000.04
Other Liabilities0.000.000.000.000.0033.2046.5043.570.47
Total Liabilities158.78106.2985.8297.93132.37127.5383.4874.715.93
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00109.23
Common Equity245.49368.63225.22260.24172.07260.77112.90106.62-53.52
Total Shareholders Equity245.49368.63225.22260.24172.07260.77112.90106.6255.71
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity245.49368.63225.22260.24172.07260.77112.90106.6255.71
Total Liabilities & Stockholders Equity404.27474.92311.04358.17304.44388.31196.38181.3461.64
Book Value Per Share2.263.932.965.044.897.643.794.07-2.12
Tangible Book Value Per Share2.263.932.965.044.897.643.794.07-2.12
Full-Time Employees2891961501141451199365-
Price to Book Ratio33.6943.706.311.595.086.363.485.655.26
Return on Assets-85.97-62.67-49.55-40.60-38.05-29.58-27.00-40.60-52.94
Return on Equity-123.08-82.95-68.30-62.22-60.90-46.29-46.46-60.77-59.70
Return on Invested Capital-108.34-57.55-59.57-41.80-54.88-27.67-43.56-46.25-44.55
Quick Ratio6.959.618.809.014.138.095.645.7211.78
Current Ratio6.959.618.809.014.138.095.645.7211.78

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-413.61-377.94-246.29-165.79-134.50-131.80-86.48-51.00-49.33
Depreciation1.311.661.942.849.889.023.872.300.81
Other Funds (Non Cash)85.7277.3036.8128.3326.3124.4311.106.574.92
Funds from Operations-326.57-298.99-207.54-134.61-98.31-98.35-71.51-41.95-43.33
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital16.86-1.056.59-10.61-34.39-28.4411.24-21.1667.90
Cash from Operating Activities-309.71-300.04-200.95-145.23-132.69-126.79-60.27-63.1224.57
Capital Expenditures-0.20-0.60-0.10-0.07-1.06-5.25-4.09-3.12-1.49
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.010.000.000.000.01-
Purchase or Sale of Investments36.28219.29-75.9641.20-170.63139.56-59.41-59.13-58.74
Purchase of Investments-72.22-98.01-293.16-290.80-300.63-60.44-200.11-235.42-75.24
Sale Or Maturity of Investments108.50317.30217.20332.00130.00200.00140.70176.2916.50
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities36.08218.69-76.0641.14-171.70134.31-63.50-62.24-60.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock261.77179.26353.15102.57195.8119.99223.2249.2694.94
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock261.77179.26353.15102.57195.8119.99223.2249.2694.94
Proceedsfrom Stock Options160.7891.660.000.000.000.00215.9248.3594.94
Issuance or Reduction of Debt, Net91.5549.140.000.00-0.9724.9824.62-0.36-0.67
Change in Long Term Debt91.5549.140.000.00-0.9724.9824.62-0.36-0.67
Issuance of Long Term Debt194.6174.660.000.000.0024.9824.620.000.00
Reduction of Long Term Debt-103.06-25.520.000.00-0.970.000.00-0.36-0.67
Net Financing Active Other Cash Flow-0.000.00-0.120.000.00-0.02-0.02-0.010.00
Other Financing Activities Uses0.000.00-0.120.000.00-0.02-0.02-0.010.00
Cash from Financing Activities353.32228.40353.03102.57194.8344.95247.8248.8894.27
Exchange Rate Effect--0.00-------
Net Change in Cash79.68147.0576.02-1.51-109.5652.48124.05-76.4758.61
Free Cash Flow-309.91-300.64-201.05-145.30-133.76-132.04-64.36-66.2323.08
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--------15.58
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.180.27

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments416.01492.09479.94367.56369.63295.01
Short Term Receivables2.371.9621.482.803.551.97
Inventories0.770.000.000.000.000.00
Other Current Assets14.2813.1413.8614.7917.5322.14
Total Current Assets433.43507.18515.28385.15390.71319.13
Net Property, Plant & Equipment8.709.7911.5712.0913.8815.55
Total Investments and Advances1.403.813.813.813.812.41
Intangible Assets0.000.000.000.000.000.00
Other Assets2.452.774.593.233.322.96
Total Assets445.97523.54535.25404.27411.72340.05
Short Term Debt Incl. Current Port. of LT Debt5.826.326.085.555.335.21
Accounts Payable6.1610.999.2210.306.761.10
Other Current Liabilities68.1454.9344.3539.5749.8844.12
Total Current Liabilities80.1272.2459.6455.4261.9750.44
Long Term Debt197.17197.52199.60103.36104.7556.32
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities277.30269.76259.24158.78166.72106.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity168.68253.78276.01245.49245.00233.29
Total Shareholders Equity168.68253.78276.01245.49245.00233.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity168.68253.78276.01245.49245.00233.29
Total Liabilities & Stockholders Equity445.97523.54535.25404.27411.72340.05
Book Value Per Share1.382.092.322.262.472.43
Tangible Book Value Per Share1.382.092.322.262.472.43
Full-Time Employees---289--
Price to Book Ratio33.6923.7321.7217.8315.3210.76
Return on Assets-96.45-94.63-86.70-85.97-119.63-111.37
Return on Equity-199.97-167.77-138.94-123.08-218.04-172.08
Return on Invested Capital-29.31-24.35-22.18-26.08-29.23-37.99
Quick Ratio5.407.028.646.956.306.33
Current Ratio5.417.028.646.956.306.33

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-107.24-109.90-105.51-90.97-102.22-110.03
Depreciation0.260.300.340.420.420.42
Other Funds (Non Cash)19.6122.4122.9920.7119.0424.35
Funds from Operations-87.37-87.19-82.19-69.83-82.75-85.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.5616.890.08-5.6613.838.32
Cash from Operating Activities-81.81-70.31-82.10-75.50-68.92-76.94
Capital Expenditures-0.10-0.00-0.07-0.03-0.08-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments8.04-5.50-5.2739.0059.7885.68
Purchase of Investments-3.96-43.00-25.270.00-18.72-21.22
Sale Or Maturity of Investments12.0037.5020.0039.0078.50106.90
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.94-5.50-5.3338.9759.7085.47
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.7383.28101.4773.2994.486.47
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.7383.28101.4773.2994.486.47
Proceedsfrom Stock Options0.0062.7798.000.0088.293.37
Issuance or Reduction of Debt, Net-0.61-0.1692.310.0024.470.00
Change in Long Term Debt-0.61-0.1692.310.0024.470.00
Issuance of Long Term Debt-0.61-0.16195.370.0049.990.00
Reduction of Long Term Debt0.000.00-103.060.00-25.520.00
Net Financing Active Other Cash Flow0.000.000.00-0.0025.520.00
Other Financing Activities Uses0.000.000.000.0025.520.00
Cash from Financing Activities3.1383.12193.7973.29144.476.47
Net Change in Cash-70.747.31106.3536.76135.2515.00
Free Cash Flow-81.91-70.31-82.17-75.53-69.01-77.16

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3023.30%23.5M100.8M1.66M
2026-10-1522.01%22.2M100.8M1.55M
2026-09-3022.57%22.7M100.7M1.44M
2026-09-1519.30%19.4M100.6M1.44M
2026-08-3118.14%18.0M99.3M1.31M
2026-08-1418.35%18.2M99.3M1.32M
2026-07-3118.04%17.7M98.0M1.39M
2026-07-1518.26%17.6M96.4M1.44M
2026-06-3019.08%18.4M96.3M1.58M
2026-06-1517.37%16.7M96.3M1.45M
2026-05-2917.05%16.4M96.4M1.55M
2026-05-1516.25%15.7M96.4M1.49M
2026-04-3015.47%14.9M96.4M1.43M
2026-04-1516.01%14.8M92.6M1.36M
2026-03-3117.54%15.7M89.7M1.30M
2026-03-1315.93%14.3M89.7M1.09M
2026-02-2718.22%14.5M79.7M1.09M
2026-02-1319.61%15.6M79.7M1.36M
2026-01-3019.09%15.5M81.4M1.46M
2026-01-1519.26%15.7M81.4M1.75M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call22.5022.3026.200.004.8530.000.000.969-0.0850.005
call25.0019.8023.700.004.2920.000.000.964-0.0840.006
call30.0015.2018.7018.003.3250.000.000.952-0.0790.007
call35.009.7013.8014.902.54724.000.000.850-0.2060.017
call40.005.108.907.001.82687.0024.000.788-0.1740.021
call45.002.503.902.821.06028028.000.632-0.1340.027
call50.000.051.000.850.76723429.000.302-0.1120.025
call55.000.050.350.160.8561,4294.000.121-0.0710.015
call60.000.050.750.201.15834.000.000.096-0.0810.012
call65.000.002.150.221.5400.000.000.103-0.1140.013
call70.000.001.850.001.7250.000.000.093-0.1190.012
call75.000.001.850.001.8520.000.000.066-0.0980.009
put22.500.002.150.002.8590.000.00-0.031-0.0830.005
put25.000.002.150.002.4970.000.00-0.036-0.0810.006
put30.000.000.300.111.86413.003.00-0.048-0.0760.007
put35.000.051.850.152.1211020.00-0.150-0.2020.017
put40.000.002.300.581.4353370.00-0.212-0.1690.021
put45.000.001.400.670.7471,2220.00-0.368-0.1290.027
put50.003.504.403.500.78713814.00-0.698-0.1060.025
put55.006.509.100.001.0911.000.00-0.879-0.0650.015
put60.0011.4014.0019.901.3730.000.00-0.904-0.0740.012
put65.0016.3020.300.002.3470.000.00-0.918-0.0810.011
put70.0021.3025.300.002.6390.000.00-0.927-0.0860.010
put75.0026.3030.300.002.8990.000.00-0.934-0.0900.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-148-KCurrent report2026-09-11SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06424B5SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-06-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1012.00M200
2026-090000
2026-080000
2026-0700923.08K5
2026-060000
2026-050000
2026-04003.15M4
2026-030000
2026-02001.83M5
2026-01007.33M10
2025-12006.21M2
2025-110000

Institutional holders

Manager% owned
FMR LLC14.95%
Siren, L.L.C.7.99%
BlackRock, Inc.7.92%
Samsara BioCapital, LLC5.76%
PRICE T ROWE ASSOCIATES INC /MD/5.67%
WELLINGTON MANAGEMENT GROUP LLP5.61%
Orbis Allan Gray Ltd4.95%
VANGUARD CAPITAL MANAGEMENT LLC3.98%
STATE STREET CORP3.95%
Redmile Group, LLC3.60%

Funds

Fund% owned
Fidelity Growth Company Fund3.72%
VANGUARD HEALTH CARE FUND3.22%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
iShares Russell 2000 ETF2.40%
MFS Mid Cap Growth Fund2.10%
T. Rowe Price New Horizons Fund, Inc.1.92%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.88%
Select Biotechnology Portfolio1.36%
Eventide Gilead Fund1.22%
Fidelity Growth Company K6 Fund1.05%

OakChart. SRRK. Cached 15 minutes.